Welcome to the Hope Bio Blog

Hope Bio’s CTTACC 2023 Recap By Jan Shultis, Ph.D. What do you get when you send two scientists and two executives to the desert? While you search for a punchline, we’ll supply our experientially discovered answer - you get great and growing industry relationships, breaking news in cell therapy and traumatic brain injury, and a whole lot o’ pictures of a cell culture flask in exotic (by cell culture flask standards) locations. CTTACC 2023 main session A huge “thank you” to Sc

A four-year, nearly $5 million clinical trial grant awarded to UTHealth Houston by the Department of Defense’s Office of Congressionally Directed Medical Research Programs (CDMRP) will evaluate if intravenously infused Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) reduce chronic neuroinflammatory response to severe traumatic brain injury (TBI). UTHealth Houston and Hope Bio celebrating completion of treatments in the Phase I trial for Trauma

By Jan Shultis, Ph.D. Sugar Land, Tx. (Apr 6, 2023) – As Houston-area biotechnology company Hope Biosciences marks their seventh year of service, the team remains fixated on other numbers—numbers of mesenchymal (adult) stem cells cultured, countries served, new products launched, and FDA-authorized clinical research studies supported thus far. The answers, a testament to that very team? Four-hundred-and-four billion stem cells cultured since inception, 140 billion in this sev